2009 Marsh and Hoskins 2010 Evrard and Mbatchi 2012 ), HLA testing for Abacavir for HIV management (Goldman and Faruki 2008 Faruki et al. Probably the best examples of pharmacogenomic applications in routine practice are HER2 testing for breast cancer treatment (Phillips 2008 ), UGT1A1 variant associated with Gilbert's disease in patient receiving irinotecan (Palomaki et al. Even though many pharmacogenomic tests are available, these test have not yet been recommended for most drugs, and large-scale trials are needed to show that routine testing could improve patient outcomes in pharmacotherapy, such as CYPD6 polymorphism on tamoxifen treatment (Lee et al. Human gut and microbiome warrant attention in future research efforts for personalized medicine, and rational therapeutics for obesity and the associated continuum of diseases. Mechanism-oriented molecular diagnostics for obesity offer the promise to substantively influence the long term trajectory of obesity related diseases and create a space whereby preventive public health interventions can be designed effectively. We also highlight that chronobiology is a potentially relevant consideration for systems biology research in obesity. This paper examines the emerging role of metabonomic-based gut microbiome biomarkers for personalized interventions against obesity. Dietary interventions and pharmacological strategies have so far failed to deliver appreciable success in the fight against obesity. The obesity spectrum diseases also impact individuals at a young age, posing a tremendous burden on the global public health system. The global figure of affected individuals is expected to increase from currently 150 million to 300 million in 2025. In the last two decades, an explosive increase in the number of persons diagnosed with diabetes has been observed worldwide. Obesity and associated diseases such as diabetes have become an epidemic that represents a major threat to global public health. Khoury is board-certified in medical genetics.
He received a PhD in human genetics/genetic epidemiology and training in medical genetics from The Johns Hopkins University. Khoury received his BS degree in biology/chemistry from the American University of Beirut, Lebanon, and his medical degree and pediatric training from the same institution. Daar (McLaughlin-Rotman Centre for Global Health and School of Public Health Sciences, University of Toronto), Serge Dubé (Department of Surgery and Faculty of Medicine, University of Montreal) and Vural Ozdemir (Editor, CPPM, and Department of Social and Preventive Medicine, Faculty of Medicine, University of Montreal). He is interviewed by a multidisciplinary team of researchers and educators: Abdallah S. Khoury shares his thoughts and immediate and long term vision on public health genomics, and why this new field of investigation is important for personalized medicine and global health.
In the September 2009 issue of the Current Pharmacogenomics and Personalized Medicine (CPPM), Dr. For more than a decade, the CDC's Office of Public Health Genomics played an important role in development of a new hybrid field of investigation, `public health genomics'. As an internationally recognized institution, CDC's mission is to protect the health and safety of people, to provide credible information to enhance health decisions, and to promote health through strong national and international partnerships. The Office was formed in 1997 to assess the impact of advances in human genetics and the Human Genome Project on public health and disease prevention. Khoury, MD, PhD is the first and current director of the Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC) in the United States.
0 kommentar(er)
